{"id":"NCT01926886","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC)","officialTitle":"A Single Arm Multi-center Study Investigating the at Home Administration of Trastuzumab Subcutaneous Vial for the Treatment of Patients With HER2-positive Early Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11-19","primaryCompletion":"2015-09-04","completion":"2017-07-19","firstPosted":"2013-08-21","resultsPosted":"2019-09-18","lastUpdate":"2019-09-18"},"enrollment":102,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"DRUG","name":"Trastuzumab","otherNames":["Herceptin"]}],"arms":[{"label":"Trastuzumab","type":"EXPERIMENTAL"},{"label":"Health Care Professionals","type":"NO_INTERVENTION"}],"summary":"This single arm, multicenter study will evaluate the safety of assisted subcutaneous administration of trastuzumab in participants with HER2+ eBC. Participants who have completed the first 6 cycles of intravenous (IV) trastuzumab as part of the (neo)adjuvant treatment will be eligible to receive a further 12 cycles of trastuzumab in this study. Participants will receive IV trastuzumab at initial loading dose of 8 milligrams per kilogram (mg/kg) body weight (BW) for three-weekly (q3w) regimen and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (cycles 7-9) in hospital followed by subcutaneous (SC) administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18).","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Up to 45 months","effectByArm":[{"arm":"Trastuzumab","deltaMin":90.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":10},"locations":{"siteCount":23,"countries":["Belgium","Israel"]},"refs":{"pmids":["32240454"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":101},"commonTop":["Fatigue","Injection site erythema","Injection site swelling"]}}